Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Barcelona, Spain – 26 Aug 2017: Women at high risk of cardiovascular events are less likely to receive recommended statin doses for secondary prevention, according to results from the DYSIS study presented today at ESC Congress.(1)
The importance of lowering low-density lipoprotein (LDL) cholesterol is undisputed, with research demonstrating that a decrease of 1 mmol/l (39 mg/dl) could reduce the five year risk of major coronary events, need for revascularisation to open blocked arteries, and stroke by approximately a fifth. Additional decreases improve outcomes even more.
This rationale is reflected by European Society of Cardiology (ESC) / European Atherosclerosis Society (EAS) guidelines, which advocate pursuing LDL cholesterol treatment targets that are defined based on a patient's risk.(2) However, many studies have shown that in real life practice the rate of achieving an LDL cholesterol target of less than 70 mg/dl for very high risk patients in secondary prevention is just 20–25%.
“Observational trials in many fields of cardiology have shown that female patients are less likely to be treated according to current guidelines,” said lead author Dr Anselm Kai Gitt, a cardiologist at Heart Centre Ludwigshafen, Germany. “We therefore raised the question of whether female sex has an impact on reaching the LDL cholesterol target of less than 70 mg/dl for secondary prevention in clinical practice.”
This study assessed how many male and female patients truly achieve treatment targets in clinical practice. The analysis was part of the multinational cross-sectional Dyslipidaemia International Study (DYSIS) in Europe, Canada, South Africa, the Middle East and China. Between 2008 and 2012, 57 855 consecutive outpatients treated with statins were enrolled into the study.
Data was collected on cardiovascular risk factors, statin treatment and dose, and LDL cholesterol level. All information was obtained under real life conditions in an outpatient setting. Each patient’s risk of a cardiovascular event was calculated using the ESC SCORE risk charts. The researchers then examined the association between female sex and achieving an LDL cholesterol level of less than 70 mg/dl in patients at very high risk of a cardiovascular event.
A total of 46 310 patients in the study were at very high risk of a cardiovascular event, of whom 18 653 (40.3%) were women. Compare to men, female patients were older, more often had risk factors such as hypertension and diabetes, but less often suffered from already manifest ischaemic heart disease.
The investigators found that women were more often treated with less potent statins as well as with lower doses of statins, independent of the statin used (table). Just 17.5% of women reached the LDL cholesterol target of less than 70 mg/dl compared to 24% of men (p < 0.001). Even after correcting for differences in baseline characteristics, female sex independently predicted failure to achieve the LDL cholesterol target in clinical practice (odds ratio, 0.68; 95% confidence interval, 0.47–0.97).
Dr Gitt said: “Women at very high risk of a cardiovascular event were treated with less potent statins and lower doses of statins in clinical practice than men. Compare to men, women had a 32% lower chance of reaching the LDL cholesterol target recommended by ESC / EAS guidelines. More research is needed to discover why women are inadequately treated so that preventable cardiovascular events can be avoided.”
Table: Baseline characteristics, statin treatment, and LDL cholesterol target achievement in women and men at very high risk of a cardiovascular event
BMI: body mass index; LDL: low-density lipoprotein; LDL-C: low-density lipoprotein cholesterol
Note: Mean BMI values are rounded and the large number of patients in the study makes even small differences significant.
Sources of funding: The study was sponsored by Merck Inc, Kenilworth, USA.
Disclosures: AKG has received honoraria for consultant and speaker honoraria from MSD, Amgen, Sanofi.
References and notes
(1) The abstract “Undertreatment of female patients in lipid-lowering for secondary prevention in Europe, Canada, South-Africa, Middle East and China: results of the dyslipidemia international study (dysis)” will be presented during:
(2) Catapano AL, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. Epub 2016 Aug 27.
ESC Press OfficeFor more information, please contact the ESC Press Office: firstname.lastname@example.org.For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856The press conference timetable is available here.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. About the European Society of CardiologyThe European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.About ESC Congress 2017ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at email@example.com.This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved